DV
Dividend Vision

PEPG — PepGen Ltd

PepGen Ltd (PEPG)

Total return is -76.8% over the past 4.3 years, 176.8 points behind SPY at 100.0%. Its deepest 1-year drawdown was 81.2%.

PepGen Ltd is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with lead programs in Phase 2 trials for myotonic dystrophy type 1. The company does not currently distribute dividends. PepGen appeals to investors seeking exposure to early-stage biotech development rather than current income.

PEPG key facts

Asset type
Stock
Asset class
Equity
Inception date
05/06/2022
Last close
$2.99
Market cap
$155,160,384
Average volume
612400.0
Beta
1.879
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.46